Want to see GB:POLB full AI Analyst Report?
POLB Stock Chart & Stats
3.55 p
0.24 p(5.04%)
At close: 4:00 PM EST
3.55 p
0.24 p(5.04%)
Day’s Range― - ―
52-Week Range2.50 p - 9.00 p
Previous CloseN/A
Volume846.29K
Average Volume (3M)1.12M
Market Cap
£43.43M
Enterprise Value20.18 p
Total Cash (Recent Filing)£7.71M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding705,103,760
10 Day Avg. Volume836,211
30 Day Avg. Volume1,116,415
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong IP & Regulatory ProgressOrphan designation plus multiple patents and projected protection to 2044 create durable exclusivity that supports long-term commercial optionality and bargaining power with partners. This IP/regulatory foundation improves potential deal economics and reduces generic risk if clinical success follows.
Low Leverage / No Reported DebtNo debt materially lowers near-term financial distress risk and preserves flexibility for partnering or milestone-driven financing. Although equity has eroded from cumulative losses, the absence of leverage makes future funding less encumbered and reduces fixed financial obligations.
Strong Early Efficacy Signal (human Challenge)Robust, dose-dependent cytokine suppression in a controlled human challenge provides a credible mechanism-of-action signal that is more predictive than in vitro data. This durable biological evidence strengthens de-risking for later development and enhances partner interest for definitive trials.
Bears Say
Pre-revenue With Sustained LossesA persistent pre-revenue operating profile means value depends entirely on successful clinical advancement and partnering. Sustained multi-year losses erode the equity base and prolong dependence on external capital, increasing dilution and execution risk before commercial revenues emerge.
Limited Cash Runway Into 2027A runway constrained to 2027 caps the company’s ability to fund larger confirmatory trials without additional financing or partner funding. This structural financing cliff creates timing pressure to secure deals or raise capital, which can alter program pacing and strategic choices.
Dependence On External Partners For Late-stage WorkRelying on third parties for pivotal trials and commercialization transfers execution and pricing risk to partners. Successful monetization requires favorable partner terms and timely interest post-readout; misaligned incentives or poor partner selection could delay approvals or reduce long-term economics.
Poolbeg Pharma Ltd. News
POLB FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest share price was 2.50 p and its highest was 9.00 p in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Poolbeg Pharma Ltd.’s market cap is £43.43M.
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Sep 08, 2026 which is in 48 days.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Apr 28, 2026. The company reported -0.005 p earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 705,103,760 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -0.005 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.371%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in GB:POLB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Poolbeg Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth £250.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Open Orphan Plc
―
Aptamer Group Plc
―